Biotech entity
Every one of those 1 sits in a single category, pharma. Zevra Therapeutics, Inc. is most often covered alongside Miplyffa, which appears in 1 of these 1 story. Zevra Therapeutics, Inc. appears in 1 tracked Biotech story from March 8, 2026.
Last mentioned: Mar 8, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Zevra Therapeutics, Inc. is most often covered alongside Miplyffa, which appears in 1 of these 1 story. Zevra Therapeutics, Inc. appears in 1 tracked Biotech story from March 8, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Zevra Therapeutics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 Earnings
Both companies report full-year 2025 results and 2026 guidance.
Olpruva Scaling
Zevra reports steady growth in urea cycle disorder market share.
Novartis Expansion
Voyager expands its capsid discovery collaboration with Novartis.
Miplyffa Approval
Zevra receives FDA approval for arimoclomol in NPC treatment.
Voyager Technologies and Zevra Therapeutics are preparing to report Q4 2025 results, highlighting a pivotal period for gene therapy platforms and rare disease commercialization. Investors are focused on Voyager's partnership revenue and Zevra's initial market traction for its newly approved NPC treatment.
Zevra Therapeutics, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
